课题基金 / 基金详情

项目摘要

项目成果

Robert Neil Eisenman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tuberous sclerosis (TS) is an autosomal dominant disease that causes widespread benign tumors in many tissues including the brain, lung, kidney, skin, eyes, and teeth. Although TS is rarely fatal it causes debilitating complications such as seizures, mental retardation, and heart obstruction. Tumors can arise throughout life, and in severe cases cause kidney or heart failure in adults. The disease is highly prevalent, affecting ~1/6000 individuals, or about 50,000 in the US population. There is no cure. Most cases of TS are caused by loss of function in one of two genes, TSC1 orTSC2, which encode a protein complex. The TSC1/2 complex mediates many of its effects by inhibiting the activity of Rheb, an essential activator of the Target-Of-Rapamycin (TOR) kinase, which is a central regulator of cell growth. TOR controls diverse metabolic processes required for cell growth including protein synthesis, nutrient import, autophagy, and transcription. It has two well-characterized targets in humans, S6K and 4EBP, but genetic analysis in Drosophila and mice indicate that these targets cannot account for the striking overgrowth phenotypes that occur in tuberous sclerosis. Moreover, it is has not been demonstrated that all of the downstream effects of TSC mutation are mediated via Rheb and/or TOR. Hence the identification and characterization of additional effectors of TSC1/2 complex is required to advance our understanding of the molecular and cellular basis of this disease. This project will use genetic and proteomic approaches in Drosophila and human cells to: 1) Evaluate the hypothesis that the TSC1/2 complex mediates all of its effects via Rheb and TOR, and; 2) Identify and characterize new gene products required for TSC1/2 and Rheb function. Such genes are expected to be effectors of deregulated cell growth in tuberous sclerosis, and as such constitute potential targets for diagnosis and treatment of the disease.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
LST8 regulates cell growth via target-of-rapamycin complex 2 (TORC2).
LST8 通过雷帕霉素靶标复合物 2 (TORC2) 调节细胞生长。
DOI: 10.1128/mcb.06474-11
发表时间: 2012
期刊: Molecular and cellular biology
影响因子: 5.3
作者: [Wang,Tao, Blumhagen,Rachel, Lao,Uyen, Kuo,Ying, Edgar,BruceA]
通讯作者: Edgar,BruceA
DOI: 10.1371/journal.pone.0044888
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者: [Brown HL, Kaun KR, Edgar BA]
通讯作者: Edgar BA
DOI: 10.1038/cddis.2013.351
发表时间: 2013-10-03
期刊: Cell death & disease
影响因子: 9
作者: []
通讯作者:
DOI: 10.1083/jcb.200904090
发表时间: 2009-09-07
期刊: The Journal of cell biology
影响因子: --
作者: [Wang T, Lao U, Edgar BA]
通讯作者: Edgar BA
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
  • 批准号:
    10662195
  • 项目类别:
  • 资助金额:
    $54.4万
  • 财政年份:
    2020
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
  • 批准号:
    10601282
  • 项目类别:
  • 资助金额:
    $14.73万
  • 财政年份:
    2020
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
  • 批准号:
    10400844
  • 项目类别:
  • 资助金额:
    $54.4万
  • 财政年份:
    2020
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
The MYC Transcription Factor Network and the Path to Cancer
  • 批准号:
    10477962
  • 项目类别:
  • 资助金额:
    $103.49万
  • 财政年份:
    2018
  • 负责人:
    Robert Neil Eisenman
  • 依托单位:
海外基金